TrumpRx Deal For Lowering Popular Weight Loss Drugs Is Not Flawless, People May End Up Paying More, Say Experts

TrumpRx Deal For Lowering Popular Weight Loss Drugs Is Not Flawless, People May End Up Paying More, Say Experts

Credits: AP

Text

Updated Nov 9, 2025 | 01:18 PM IST

SummaryTrump touted a new TrumpRx deal promising obesity drugs like Wegovy and Zepbound for about $250 monthly, but experts warn the plan is unclear, includes unapproved products, and only discounts low doses. Since effective treatment needs higher doses, patients may ultimately pay far more than advertised in the long run, too.

End of Article